No black box warning on record for Veozah

As of the latest FDA labeling reviewed, Veozah (FEZOLINETANT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Veozah medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Cases of hepatotoxicity and jaundice have been reported in the postmarketing setting. Perform hepatic laboratory tests prior to initiation of VEOZAH to evaluate for hepatic function and injury. Perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy. Advise patients to discontinue VE

No black box warning on record for Veozah

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hepatotoxicity: Cases of hepatotoxicity and jaundice have been reported in the postmarketing setting. Perform hepatic laboratory tests prior to initiation of VEOZAH to evaluate for hepatic function and injury. Perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy. Advise patients to discontinue VE

Veozah Black Box Warning

No black box warning on record for Veozah

Other warnings & precautions

Veozah Black Box Warning

No black box warning on record for Veozah

Other warnings & precautions